NBTX Nanobiotix S.A. - ADRs
Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:NANO.
$3.45 -0.04 (-1.15%)
As of 03/17/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: France
Country of incorporation:
IPO date: 12/11/2020
Outstanding shares: 34,875,872
Average volume: 573
Market cap: $120,321,758
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%